LUPIN
₹1,634.4
9.85 (0.61%)
  • Advice
  • Hold
03 March, 2024 10:55 BSE: 500257 NSE: LUPINISIN: INE326A01037

Start SIP in Lupin

Start SIP

Lupin Performance

Day Range

  • Low 1,624
  • High 1,645
₹ 1,634

52 Week Range

  • Low 628
  • High 1,700
₹ 1,634
  • Open Price1,630
  • Previous Close1,625
  • Volume76546

Lupin Share Price

  • Over 1 Month 8.76%
  • Over 3 Month 26.05%
  • Over 6 Month 49.42%
  • Over 1 Year 147.73%

Lupin Key Statistics

P/E Ratio 41.6
PEG Ratio 0.1
Market Cap Cr 74,468
Price to Book Ratio 5.9
EPS 9
Dividend 0.2
Relative Strength Index 69
Money Flow Index 50.59
MACD Signal 44.78
Average True Range 36.36
Lupin Financials
IndicatorDec 2023Sep 2023Jun 2023Mar 2023
Oper Rev Qtr Cr 4,1163,5603,4962,745
Operating Expenses Qtr Cr 2,8982,8242,7912,574
Operating Profit Qtr Cr 1,217835705262
Depreciation Qtr Cr 145149140146
Interest Qtr Cr 11151629
Tax Qtr Cr 16814710023
Net Profit Qtr Cr 916549477119
IndicatorMar 2023
Total Revenue Annual Cr 11,350
Operating Expenses Annual Cr 10,176
Operating Profit Annual in Cr 1,083
Depreciation Cr 548
Interest Annual Cr 98
Tax Annual Cr 102
Net Profit Annual Cr 425
IndicatorMar 2023
Cash from Operating Activity Annual Cr 1,794
Cash from Investing Activity Annual Cr -1,269
Cash from Financing Annual Activity Cr -498
Net Cash Flow Annual Cr 27
IndicatorMar 2023
Total ShareHolders Funds Annual Cr 18,412
Fixed Assets Annual Cr 4,949
Total Non Current Assets Annual Cr 15,113
Total Current Assets Annual Cr 7,571
Total Assets Annual Cr 22,684
IndicatorMar 2023
Book Value Per Share Annual Rs 405
ROE Annual % 2
ROCE Annual % 3
Total Debt to Total Equity Annual -
EBDIT Annual Margin % 10
IndicatorDec 2023Sep 2023Jun 2023Mar 2023
Oper Rev Qtr Cr 5,1974,9394,8144,330
Operating Expenses Qtr Cr 4,1594,1213,9583,852
Operating Profit Qtr Cr 1,038918856578
Depreciation Qtr Cr 257248235264
Interest Qtr Cr 74818693
Tax Qtr Cr 11713410516
Net Profit Qtr Cr 613489452236
IndicatorMar 2023
Total Revenue Annual Cr 16,715
Operating Expenses Annual Cr 14,844
Operating Profit Annual in Cr 1,798
Depreciation Cr 881
Interest Annual Cr 274
Tax Annual Cr 269
Net Profit Annual Cr 430
IndicatorMar 2023
Cash from Operating Activity Annual Cr 1,897
Cash from Investing Activity Annual Cr -1,287
Cash from Financing Annual Activity Cr -337
Net Cash Flow Annual Cr 273
IndicatorMar 2023
Total ShareHolders Funds Annual Cr 12,465
Fixed Assets Annual Cr 7,374
Total Non Current Assets Annual Cr 10,505
Total Current Assets Annual Cr 12,451
Total Assets Annual Cr 22,956
IndicatorMar 2023
Book Value Per Share Annual Rs 276
ROE Annual % 3
ROCE Annual % 7
Total Debt to Total Equity Annual -
EBDIT Annual Margin % 11

Lupin Technicals

EMA & SMA

Current Price
₹1,634.4
9.85 (0.61%)
pointer
  • Bullish Moving Average
  • ___
  • 16
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • ₹1,590.23
  • 50 Day
  • ₹1,498.68
  • 100 Day
  • ₹1,378.35
  • 200 Day
  • ₹1,214.17
  • 20 Day
  • ₹1,607.52
  • 50 Day
  • ₹1,487.79
  • 100 Day
  • ₹1,347.55
  • 200 Day
  • ₹1,165.07

Lupin Resistance and Support

PIVOT
₹1,634.42
Resistance
First Resistance 1,644.98
Second Resistance 1,655.57
Third Resistance 1,666.13
RSI 69.00
MFI 50.59
MACD Single Line 44.78
MACD 39.08
Support
First Resistance 1,623.83
Second Resistance 1,613.27
Third Resistance 1,602.68

Lupin Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 855,185 50,028,323 58.5
Week 1,579,113 90,214,703 57.13
1 Month 1,665,968 87,046,852 52.25
6 Month 1,316,985 61,318,823 46.56

Lupin Result Highlights

Lupin Synopsis

NSE-Medical-Generic Drugs

Lupin Ltd. is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 11258.83 Cr. and Equity Capital is Rs. 91.00 Cr. for the Year ended 31/03/2023. Lupin Ltd. is a Public Limited Listed company incorporated on 01/03/1983 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24100MH1983PLC029442 and registration number is 029442.
Market Cap 74,019
Sales 14,107
Shares in Float 24.15
No of funds 690
Yield 0.25
Book Value 4.01
U/D Vol ratio 3.1
LTDebt / Equity
Alpha 0.31
Beta 0.49

Lupin

Owner NameDec-23Sep-23Jun-23Mar-23
Promoters 47.04%47.06%47.07%47.08%
Mutual Funds 18.92%16.71%17%16.96%
Insurance Companies 9.7%12.26%11.84%11.73%
Foreign Portfolio Investors 16.11%14.99%13.93%13.32%
Financial Institutions/ Banks 0.14%0.14%0.14%0.14%
Individual Investors 5.87%6.24%7.06%7.86%
Others 2.22%2.6%2.96%2.91%

Lupin Management

Name Designation
Mrs. Manju D Gupta Chairman
Mr. Nilesh D Gupta Managing Director
Mr. Ramesh Swaminathan Executive Director & Global CFO
Ms. Vinita Gupta Director & CEO
Mr. Jean-Luc Belingard Independent Director
Mr. K B S Anand Independent Director
Dr. Punita Kumar-Sinha Independent Director
Mr. Mark D McDade Independent Director

Lupin Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Lupin Corporate Action

Date Purpose Remarks
2024-02-07 Quarterly Results
2023-11-08 Quarterly Results
2023-08-03 Quarterly Results
2023-05-09 Audited Results & Final Dividend
2023-02-09 Quarterly Results
Date Purpose Remarks
2023-07-14 FINAL Rs.4.00 per share (200%)Final Dividend
2022-07-15 FINAL Rs.4.00 per share(200%)Final Dividend
2021-07-28 FINAL Rs.6.50 per share(325%)Final Dividend

About Lupin

Dr Desh Bandhu Gupta founded in 1968 in Mumbai, Lupin is one of the top pharmaceutical manufacturers. It has 15 manufacturing facilities, 6 API facilities, 7 research facilities and more than 23 global offices. 

Lupin ranks 6th by sales in India. It ranks #2 in respiratory and #3 in cardiac and anti-diabetes segments. While the market growth in the chronic disease portfolio has been 11% in the last five years, Lupin has been growing at 14% YoY.
 
Over the last 4 years, it has invested over $1bn in R&D in areas of biosimilars, complex generics, long-acting complex injectables, inhalation and speciality portfolio. 

Business Verticals

1. Global Formulations
2. Active Pharmaceuticals Ingredients (API)
3. Biotech
4. Specialty Business
5. Over The Counter (OTC)
6. Biosimilars
7. Generic drugs


Company History

Lupin commenced operations in 1968 on Gudi Padwa as a vitamins manufacturer. It is named after the Lupin flower, which can tolerate infertile soils and poor climatic conditions. Its first major order was iron and folic acid tablets for mother and child healthcare programmes backed by the Government of India.

Today, it develops branded and generic formulations, APIs, and biotechnology products and sells across 100 markets, including the US, Japan, and Mexico. Lupin is one of the world's largest manufacturers of TB drugs. The company has a significant market share across multiple therapy areas such as Cardiovascular, Diabetology, Asthma, Paediatric, Central Nervous System, Gastro-Intestinal, Anti-Infective, and Non-Steroidal Anti-Inflammatory Drugs. 
 

Milestones
 

1968 - Dr Desh Bandhu Gupta started Lupin.

1972 - Lupin Laboratories Pvt. Ltd. was incorporated.

1979 - They commissioned the first formulation plant and R&D Centre at Aurangabad.

1981 - They started the production of Ethambutol.

1987 - Cephalexin plant at Mandideep and 7 ADCA plants at Ankleshwar went on stream.

1988 - Commenced Lupin Human Welfare and Research Foundation (LHWRF).

1989 - Started Lupin Chemicals (Thailand) Ltd. Received U.S. FDA approvals for the Ankleshwar and Mandideep plants.

1991 - Initiated the production of injectable Cephalosporin at Mandideep.

1992 - Commenced a sterile fermentation plant for injectable Cephalosporins at Mandideep.

1993 - Lupin Laboratories Ltd. and Lupin Chemicals Ltd. floated their IPOs.

1997 - Three facilities received U.S. FDA approvals.

2000 - Another plant received US FDA approval.

2001 - Lupin Laboratories Ltd. amalgamated with Lupin Chemicals Ltd. to form Lupin Ltd. and established the Lupin Research Park in Pune. Lupin became the only Asian pharmaceutical company to receive U.S. FDA approvals for its sterile Cephalosporin facility.

2002 - ORG-Marg rated Rablet as the 2nd best launch of 2002-03; patent filings exceed 100.

2003 - Received WHO approval for the formulation plant at Aurangabad. Lupin Pharmaceuticals Inc. USA is formed.

2004 - Started U.S. brands’ business with the launch of Suprax.

2005 - Commenced its generics business in the U.S. Implemented ESOP.

2006 - Announced the issue of FCCBs, with a listing on the Singapore Stock Exchange.

2007 - Acquired Kyowa Pharmaceuticals of Japan; and Rubamin Laboratories of India.

2008 - Acquired Hormosan Pharma GmbH, Germany. Also acquired stakes in Generic. Health Pty Ltd., Australia and Pharma Dynamics, South Africa.

2009 - Acquired majority stake in Multi-Care Pharmaceuticals Inc., Philippines.

2010 - Lupin ranked the 5th largest generic player in the U.S.

2011 - Began commercial production at the new oral solid dosage facility at Pithampur; acquired I’rom Pharmaceuticals, Japan and of worldwide rights for the Goanna Brand.

2012 - Lupin enters Nifty 50.

2014 - Acquired Nanomi BV of the Netherlands and Laboratorios Grin S.A. De C.V., Mexico.

2015 - Acquired Pharma Dynamics, South Africa, Medquimica Industria, Brazil; Specialty product portfolio of Temmler Pharma GMBH & Co., Germany.

2016 - Acquired Gavis Pharma, U.S; launched a new plant at Tottori, Japan.

2017 - Launched Softovac in the OTC segment; acquired Symbiomix Therapeutics, U.S.

2019 - Divestment of Kyowa Pharmaceutical Industry Co. Ltd., in Osaka.

2020 - Launched Etanercept Biosimilar in EU and gProAir, a key inhalation product.

Lupin FAQs

What is Share Price of Lupin ?

Lupin share price is ₹1,634 As on 03 March, 2024 | 10:42

What is the Market Cap of Lupin ?

The Market Cap of Lupin is ₹74467.7 Cr As on 03 March, 2024 | 10:42

What is the P/E ratio of Lupin ?

The P/E ratio of Lupin is 41.6 As on 03 March, 2024 | 10:42

What is the PB ratio of Lupin ?

The PB ratio of Lupin is 5.9 As on 03 March, 2024 | 10:42

What were the company's reported sales and net income in 2022?

For the year ending March 2022, Lupin reported a consolidated sales figure of INR 16,405 crores and a net loss of INR 1,528 crores. Its standalone sales and net loss for the same period stood at INR 11,772 crores and 189 crores respectively.

What is the future of Lupin Limited's shares?

Lupin’s future looks slightly bleak. The company has shown a negative net profit growth rate of 2.18% and revenue growth of 3.10% for the past 3 years. However, the company is virtually debt-free.

How to buy Lupin’s shares?

You can easily buy and sell the company's shares by creating a Demat account with 5Paisa.
 

Q2FY23